We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

95 hedge funds and large institutions have $317M invested in Viracta Therapeutics, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 22 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

288% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 8

131% more call options, than puts

Call options by funds: $9.11M | Put options by funds: $3.94M

81% more capital invested

Capital invested by funds: $175M → $317M (+$142M)

45% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 22

30% more funds holding

Funds holding: 73 → 95 (+22)

Holders
95
Holders Change
+22
Holders Change %
+30.14%
% of All Funds
2.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
32
Reduced
22
Closed
8
Calls
$9.11M
Puts
$3.94M
Net Calls
+$5.17M
Net Calls Change
+$3.45M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.5M
2
Franklin Resources
Franklin Resources
California
+$10.3M
3
PCM
Palisade Capital Management
New Jersey
+$7.64M
4
O
OrbiMed
New York
+$6.64M
5
HM
HealthCor Management
New York
+$3.82M

Top Sellers

Rank Fund Capital Flow
1
BA
BlackRock Advisors
Delaware
-$5.69M
2
CI
Cowen Inc
New York
-$3.44M
3
DCM
Decade Capital Management
New York
-$2.17M
4
Millennium Management
Millennium Management
New York
-$2.06M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Sigma Capital Management
Connecticut
$2.12M +$1.77M +1,524 New
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$1.84M -$1.56M -1,341 -50%
Millennium Management
28
Millennium Management
New York
$1.77M -$2.06M -1,768 -58%
U
29
UBS
Switzerland
$1.72M +$463K +398 +48%
IGIM
30
I.G. Investment Management
Manitoba, Canada
$1.53M -$349K -300 -21%
First Eagle Investment Management
31
First Eagle Investment Management
New York
$1.45M -$113K -97 -8%
SGAM
32
Smith Group Asset Management
Texas
$1.41M -$6.98K -6 -0.6%
GPP
33
Great Point Partners
Connecticut
$1.28M +$1.07M +922 New
EIM
34
Essex Investment Management
Massachusetts
$1.25M -$16.3K -14 -2%
Geode Capital Management
35
Geode Capital Management
Massachusetts
$1.19M +$207K +178 +26%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.13M +$11.6K +10 +1%
EI
37
EAM Investors
California
$1.07M +$899K +773 New
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$1.02M +$285K +245 +44%
RPAM
39
Rhenman & Partners Asset Management
Sweden
$974K +$816K +702 New
Ameriprise
40
Ameriprise
Minnesota
$933K +$780K +671 +67,100%
TCIM
41
TIAA CREF Investment Management
New York
$917K +$59.3K +51 +8%
MAA
42
Managed Account Advisors
New Jersey
$914K +$766K +659 New
TC
43
TFS Capital
Pennsylvania
$887K +$743K +639 New
MCM
44
Munder Capital Management
Michigan
$851K – – –
PI
45
Putnam Investments
Massachusetts
$757K +$635K +546 New
TD Asset Management
46
TD Asset Management
Ontario, Canada
$713K +$54.6K +47 +10%
BIM
47
BlackRock Investment Management
Delaware
$684K +$75.6K +65 +15%
HVC
48
Healthcare Value Capital
New Jersey
$682K +$110K +95 +24%
AIG
49
American International Group
New York
$616K -$4.65K -4 -0.9%
EAM
50
Eventide Asset Management
Massachusetts
$607K – – –
1
2
3 4 5

VIRX Hedge Fund Activity: Q1 2014 in Review

95 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2014, worth a combined $317M — up 81% from $175M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new VIRX positions and 8 closed out — a net gain of 23 holders — while 32 added to existing stakes and 22 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $18.5M. The largest seller was BlackRock Advisors, cutting an estimated $5.69M.

  • 95 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2014, up from 73 in Q4 2013.
  • Funds reported $317M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2014, up 81% quarter-over-quarter.
  • 31 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2014 and 8 closed out, a net change of +23 holders.
  • The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2014 was Fidelity Investments, an estimated $18.5M added.
  • The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2014 was BlackRock Advisors, an estimated $5.69M sold.

Based on aggregated 13F filings for Q1 2014.